secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023058
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024
---------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.
- Rezatapopt Phase 1 data: confirmed ORR 38% at RP2D (2000 mg daily), median DOR 7 months in TP53 Y220C/KRAS WT patients.
- Registrational Phase 2 portion of PYNNACLE trial on track to initiate Q1 2024; FDA alignment on RP2D and key Phase 2 design elements.
- Phase 1 analysis in ovarian cancer subgroup selected as late-breaking oral presentation at 2024 SGO Annual Meeting on March 18.
- Net loss $69.0M vs $73.3M in 2022; R&D expenses $55.9M, G&A $24.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/0000950170-24-023058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/pmvp-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer